GSK raised its full-year guidance after second quarter core earnings rose 13%, helped by higher sales in oncology, HIV and its general medicines portfolio.
GSK Lifts Outlook as Earnings Rise
GSK raised its full-year guidance after second quarter core earnings rose 13%, helped by higher sales in oncology, HIV and its general medicines portfolio.